Moscow, June 15, 2015 - The Board of Directors of PJSC Pharmstandard (LSE: PHST, ÐÒÑ: PHST RU) (the Company) decided: to acknowledge that the purchase price of US$5.50 per GDR, as it is indicated in the Tender offer made by Augment Investments Limited on May 14, 2015, inter alia, with consideration of the opinion on the fairness of purchase price provided by the independent consultant, whose engagement was approved by the Board of Directors on May 28, 2015, is fair and to recommend GDR holders to accept the Tender offer made by Augment Investments Limited.